Ranbaxy, Zenotech in pact

HYDERABAD: Hyderabad-based Zenotech Labs, a biotech-based specialty injectables company, and pharma major Ranbaxy Labs have entered into a global development and marketing agreement for launching a biosimilar product, G-CSF (filgrastim). The alliance combines Ranbaxy's regulatory and front-end capabilities and Zenotech's expertise in the manufacture of biosimilar products. For Ranbaxy, the pact signals its foray into the bio-similars space.